¶ Inflammasome
¶ Definition
Multi-protein intracellular complexes that function as danger-sensing platforms within innate immune cells, detecting both pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Upon activation, inflammasomes oligomerize to recruit and activate caspase-1, which proteolytically cleaves pro-IL-1β and pro-IL-18 into their mature, bioactive forms and triggers pyroptosis—a form of inflammatory cell death that amplifies the danger signal. The NLRP3 inflammasome is the most clinically relevant, responding to metabolic danger signals including Uric acid crystals, ATP, cholesterol crystals, islet amyloid, Saturated Fatty Acids, ceramides, and mitochondrial ROS.
¶ Picture It
Think of the inflammasome as a smoke detector in a building—but one that requires two distinct signals before it screams. The first signal (priming) is like installing fresh batteries: a TLR alarm button gets pushed by a pathogen fragment, which tells the cell's NF-κB factory to manufacture the smoke detector components (NLRP3 protein) and the alarm bells themselves (pro-IL-1β and pro-IL-18). But the detector still sits dormant. The second signal (activation) is like actual smoke entering the room: metabolic debris—Uric acid crystals from dying cells, cholesterol crystals from atherosclerotic plaques, ATP leaking from damaged mitochondria, or ROS flooding out of stressed powerhouses. When this "smoke" arrives, the detector components snap together like LEGO bricks (oligomerization), forming a platform that activates the building's fire alarm (caspase-1). This alarm doesn't just ring—it physically breaks open the alarm bells (cleaves pro-IL-1β) to release their shrieking sound (mature IL-1β). And here's the kicker: the alarm also triggers the cell to blow itself up (pyroptosis), scattering its inflammatory debris to neighbouring smoke detectors, spreading the alarm through the entire neighbourhood. The NLRP3 detector is the most sensitive and responds to over 50 different types of "smoke"—making it the hypersensitive system that connects metaflammation, metabolic disease, and chronic inflammation.
¶ Mechanism
Inflammasome activation requires a strict two-signal model:
Signal 1 – Priming (Transcriptional Upregulation):
- TLR activation (TLR4 binding LPS, TLR2 binding bacterial lipoproteins) → MyD88 adaptor recruitment → IRAK4 kinase activation → NF-κB translocation to nucleus
- NF-κB drives transcription of: NLRP3 gene, IL1B gene (encoding pro-IL-1β), IL18 gene (encoding pro-IL-18)
- Post-translational priming: deubiquitination of NLRP3 protein by BRCC3, making it assembly-competent
- Timeframe: 3-6 hours for maximal mRNA and protein accumulation
Signal 2 – Activation (Assembly and Caspase Activation):
graph TD
A[Activation Triggers] --> B{NLRP3 Sensor}
A --> |"K⁺ efflux (P2X7 receptor)"| B
A --> |"Mitochondrial ROS"| B
A --> |"Lysosomal rupture (crystals)"| B
A --> |"Cardiolipin exposure"| B
B --> C[NLRP3 Oligomerization]
C --> D[ASC Adaptor Recruitment]
D --> E[ASC Polymerization into Speck]
E --> F[Pro-Caspase-1 Recruitment]
F --> G[Proximity-Induced Caspase-1 Activation]
G --> H["Cleaves Pro-IL-1β → Mature IL-1β"]
G --> I["Cleaves Pro-IL-18 → Mature IL-18"]
G --> J["Cleaves Gasdermin D → GSDMD-NT"]
J --> K[GSDMD-NT Pores in Membrane]
K --> L["Pyroptosis + IL-1β/IL-18 Release"]
K --> M[ASC Speck Release]
M --> N[Extracellular ASC Seeds Neighbouring Cells]
Specific Activators and Mechanisms:
- ATP: Extracellular ATP (>100 μM) → P2X7 purinergic receptor → K⁺ efflux → NLRP3 conformational change
- Uric acid crystals: Phagocytosis → lysosomal destabilization → cathepsin B release into cytosol → NLRP3 activation (threshold: >6.8 mg/dL serum urate triggers crystal formation)
- Cholesterol crystals: In atherosclerotic plaques → macrophage uptake → lysosomal damage → NLRP3 oligomerization
- Mitochondrial ROS: Complex I/III leakage → O₂⁻ production → oxidized mitochondrial DNA (mtDNA) release → NLRP3 binding to oxidized mtDNA
- Ceramides and Saturated Fatty Acids: Palmitate (C16:0) → de novo ceramide synthesis → mitochondrial dysfunction → ROS → NLRP3 activation (the metaflammation link)
- Islet amyloid (IAPP): In Type 2 Diabetes β-cells → amyloid fibril phagocytosis → lysosomal rupture → NLRP3-driven IL-1β kills neighbouring β-cells
Downstream Effects:
- Mature IL-1β (17 kDa) secreted → binds IL-1 receptor (IL-1R1) on target cells → MyD88/IRAK signaling → NF-κB and AP-1 activation → amplification of inflammatory gene expression (fever, acute phase proteins, Insulin resistance)
- Mature IL-18 (18 kDa) secreted → binds IL-18Rα/β → induces IFN-γ from NK cells and Th1 cells
- Gasdermin D N-terminal fragment (GSDMD-NT) oligomerizes in plasma membrane → forms 10-15 nm pores → cell swelling, lysis, and release of intracellular DAMPs (pyroptosis)
- ASC specks (0.8-1 μm protein aggregates) released from dying cells → phagocytosed by neighbouring macrophages → seed inflammasome assembly in recipient cells (prion-like spreading)
Negative Regulation:
- β-hydroxybutyrate (ketone body, >1 mM) → inhibits K⁺ efflux → blocks NLRP3 oligomerization (mechanism underlying ketogenic diet anti-inflammatory effects)
- Autophagy (via BNIP3/BNIP3L) → removes damaged mitochondria → reduces mtROS trigger
- SOCS proteins (SOCS1, SOCS3) → degrade NLRP3 mRNA and protein
- cAMP/PKA pathway → phosphorylates NLRP3 → prevents oligomerization
¶ Clinical Significance
The inflammasome is the molecular bridge linking metabolic dysfunction to chronic inflammation—the selfish immune system responding to a mismatch environment rich in processed foods, sedentary behavior, and chronic stress. In cPNI practice, inflammasome hyperactivation manifests across multiple systems:
Metabolic Diseases:
- Type 2 Diabetes: Islet amyloid deposits activate NLRP3 in pancreatic β-cells → autocrine IL-1β drives β-cell death and reduces Insulin secretion. The CANTOS trial (canakinumab, anti-IL-1β antibody) reduced cardiovascular events by 15% in patients with prior myocardial infarction and CRP >2 mg/L, validating the inflammasome as a therapeutic target
- Gout: Serum urate >6.8 mg/dL → monosodium urate crystal formation in joints → NLRP3 activation in synovial macrophages → IL-1β surge drives acute inflammatory arthritis. Colchicine works partly by disrupting microtubule assembly required for NLRP3 speck formation
- Atherosclerosis: Cholesterol crystals in arterial plaques → macrophage NLRP3 activation → IL-1β promotes endothelial dysfunction, smooth muscle proliferation, and plaque instability
- Obesity and metaflammation: Saturated Fatty Acids (especially palmitate) → ceramide accumulation → mitochondrial stress → chronic low-grade NLRP3 activation in adipose tissue macrophages → Insulin resistance via IL-1β-mediated IRS-1 serine phosphorylation
Neurodegenerative Diseases:
- Alzheimer's Disease: Amyloid-β oligomers → microglial NLRP3 activation → IL-1β drives tau hyperphosphorylation and synaptic loss. ASC specks released from dying microglia seed Aβ aggregation in neighbouring cells
- Parkinson's Disease: α-synuclein aggregates activate NLRP3 in nigral microglia → dopaminergic neuron death
Autoimmune Conditions:
- Crohn's Disease and Ulcerative Colitis: Gut dysbiosis → increased ATP and bacterial products → intestinal epithelial NLRP3 activation → IL-18 drives intestinal barrier breakdown
- Rheumatoid arthritis: Synovial NLRP3 activation drives IL-1β-mediated cartilage degradation
Intervention Implications (Metamodel Integration):
- Metamodel 5 (Selfish Systems): The inflammasome represents the immune system's selfish prioritization of danger response over metabolic stability—it will sacrifice β-cells, neurons, and joints to eliminate perceived threats
- Evolutionary Mismatch: NLRP3 evolved to detect acute infections and tissue damage, not chronic exposure to Saturated Fatty Acids, Advanced glycation end-products, and Uric acid from high-fructose diets. Modern metaflammation is the inflammasome responding to a world it wasn't designed for
- Therapeutic Strategies:
- Ketogenic diet or Intermittent fasting → β-hydroxybutyrate >1 mM inhibits NLRP3
- Omega-3 fatty acids (EPA/DHA) → reduce mitochondrial ROS, shift lipid mediator production toward Resolvins and Protectins
- Colchicine (0.5-1 mg/day) → disrupts microtubule-dependent NLRP3 assembly
- Canakinumab or anakinra (IL-1 blockade) for refractory cases
- Target upstream metabolic triggers: reduce fructose intake (lowers Uric acid), increase fiber (reduces LPS translocation), optimize mitochondrial function (Q10, NAC, Magnesium)
Clinical Thresholds:
- IL-1β >5 pg/mL in serum suggests inflammasome activation (normal
pg/mL) - CRP >2 mg/L correlates with cardiovascular risk mediated by IL-1β
- Serum Uric acid >6.8 mg/dL: crystal formation threshold
- ASC specks detectable in CSF of Alzheimer's patients (research marker)
¶ Key Facts
- NLRP3 is the most versatile pattern recognition receptor, responding to over 50 chemically distinct activators—from viral RNA to silica crystals to ATP
- The two-signal requirement prevents accidental activation: Signal 1 loads the gun (transcription), Signal 2 pulls the trigger (oligomerization)
- ASC specks function as extracellular "danger seeds"—released ASC aggregates are phagocytosed by neighbouring macrophages and nucleate inflammasome assembly without requiring Signal 2, creating a feed-forward inflammatory loop
- β-hydroxybutyrate at ≥1 mM directly inhibits NLRP3 by preventing K⁺ efflux, explaining why ketogenic diets reduce seizures (via reduced neuroinflammation) and improve metabolic syndrome
- The CANTOS trial (2017) demonstrated that canakinumab (anti-IL-1β, 150 mg SC every 3 months) reduced cardiovascular events by 15% independently of lipid lowering, proving the "inflammatory hypothesis" of atherosclerosis
- IL-1β induces fever by acting on the hypothalamus to increase prostaglandin E2 (PGE2) synthesis, which raises the thermoregulatory set point—NSAIDs reduce fever by blocking COX-2
- Mitochondrial ROS are obligatory for NLRP3 activation: antioxidants targeting mitochondria (MitoQ, MitoTEMPO) block inflammasome assembly in vitro
- Colchicine's anti-inflammatory mechanism includes disrupting microtubule-dependent transport of NLRP3 components to the assembly site, in addition to reducing neutrophil chemotaxis
- Uric acid crystals activate NLRP3 via lysosomal rupture and cathepsin B release—this explains why allopurinol (xanthine oxidase inhibitor) treats gout by preventing crystal formation at the source
- Trained immunity can enhance NLRP3 responsiveness: β-glucan exposure epigenetically reprograms monocytes to hyper-respond to subsequent NLRP3 triggers, increasing IL-1β output 2-5 fold
- NLRP3 gain-of-function mutations cause cryopyrin-associated periodic syndromes (CAPS)—patients have spontaneous IL-1β release, fevers, and systemic inflammation treatable with IL-1 blockade
¶ Connections
- IL-1β — primary mature cytokine product cleaved and secreted by activated inflammasomes, drives fever, acute phase response, and Insulin resistance
- caspase-1 — inflammatory cysteine protease recruited and activated by inflammasome platforms to cleave pro-IL-1β, pro-IL-18, and gasdermin D
- NLRP3 inflammasome — most clinically relevant inflammasome subtype, responds to metabolic danger signals and drives chronic inflammatory diseases
- NOD-Like Receptors — cytosolic pattern recognition receptor family including NLRP3, NLRP1, NLRC4, and AIM2, which form inflammasomes
- DAMPs — endogenous danger molecules (ATP, uric acid, cholesterol crystals, mtDNA) that provide Signal 2 for inflammasome activation
- PAMPs — pathogen-associated molecular patterns (LPS, flagellin, viral RNA) that provide Signal 1 via TLR priming
- NF-κB — transcription factor activated by Signal 1, drives expression of NLRP3, pro-IL-1β, and pro-IL-18 genes during priming phase
- pyroptosis — gasdermin D-mediated inflammatory cell death triggered by active caspase-1, releases intracellular contents and amplifies danger signaling
- ROS — reactive oxygen species, particularly mitochondrial superoxide, required as obligatory Signal 2 for NLRP3 oligomerization
- ATP — extracellular adenosine triphosphate released from damaged cells, activates P2X7 receptor causing K⁺ efflux that triggers NLRP3
- Uric acid — when >6.8 mg/dL forms monosodium urate crystals that activate NLRP3 via lysosomal rupture, causing Gout inflammation
- Type 2 Diabetes — islet amyloid (IAPP) deposits activate β-cell NLRP3, driving IL-1β-mediated β-cell death and insulin deficiency
- Atherosclerosis — cholesterol crystals in arterial plaques activate macrophage NLRP3, promoting plaque inflammation and instability
- metaflammation — chronic low-grade inflammation driven by metabolic danger signals (saturated fats, ceramides, uric acid) activating adipose tissue inflammasomes
- β-hydroxybutyrate — ketone body produced during fasting/ketosis that directly inhibits NLRP3 assembly by blocking K⁺ efflux
- mitochondrial dysfunction — produces ROS and releases oxidized mtDNA that activate NLRP3, linking metabolic stress to inflammation
- ASC — adaptor protein (apoptosis-associated speck-like protein containing a CARD) essential for bridging NLRP3 to pro-caspase-1, forms prion-like aggregates
- Trained immunity — epigenetic reprogramming of monocytes/macrophages that enhances NLRP3 inflammasome responsiveness to subsequent triggers
- TLR — toll-like receptors provide Signal 1 by recognizing PAMPs and activating NF-κB-dependent inflammasome priming
- Alzheimer's Disease — amyloid-β activates microglial NLRP3, driving IL-1β production that exacerbates tau pathology and neurodegeneration
- Saturated Fatty Acids — especially palmitate, trigger ceramide synthesis and mitochondrial stress, activating adipose tissue NLRP3 in obesity
- Insulin — IL-1β from inflammasome activation phosphorylates IRS-1 on serine residues, blocking insulin receptor signaling and causing resistance
- Resolvins — specialized pro-resolving mediators derived from omega-3s that suppress NLRP3 activation and promote resolution
- COX-2 — cyclooxygenase enzyme induced by IL-1β, produces PGE2 driving fever and pain—target of NSAIDs that reduce inflammasome-mediated symptoms
- Autophagy — cellular recycling process that removes damaged mitochondria (mitophagy), reducing ROS-driven NLRP3 activation
¶ Module References
- Module 5